![Breast cancer stained with BCA-225 [Cu-18] antibody](https://biocare.net/wp-content/uploads/3241-1.jpg "Breast cancer stained with BCA-225 [Cu-18] antibody")
BCA-225 [Cu-18]
Price range: $269.00 through $655.00
Description
Product Description
BCA-225 (Breast Cancer Antigen 225) is a 225 kD glycoprotein present in human breast carcinoma cells, as well as adenocarcinomas of the breast, kidney, ovary, and lung (1,2). Antibody clone Cu-18 was identified as specifically recognizing BCA-225 in breast carcinomas, in both the primary tumor and its metastatic derivatives (3,4). BCA-225 is considered to be a highly sensitive marker of mammary tissue (1,3).
Specifications
Specifications
| Intended Use | |
|---|---|
| Clone | |
| Source | |
| Species Reactivity | |
| Isotype | |
| Positive Control |
Datasheets & SDS
| Download Data Sheet |
| Download UltraLine & ONCORE Pro Data Sheet |
| Download RUO Data Sheet |
| Download SDS Sheet |
Browse more documents for this product (IFUs, datasheets, translations, SDS, and more).
References
1. Mesa-Tejada R, et al. Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies. Am J Pathol. 1988 Feb;130(2):305-14. 2. Loy TS, et al. Distribution of BCA-225 in Adenocarcinomas. An Immunohistochemical Study of 446 Cases. Am J Clin Pathol. 1991 Sep;96(3):326-9. 3. Brown RW, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997 Jan;107(1):12-9. 4. Zombori T, Cserni G. Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5. Pathol Oncol Res. 2018 Apr;24(2):259-67. 5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.” 6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.
